General Information of Drug (ID: DMFWXPS)

Drug Name
PMID29130358-Compound-Figure10(2a) Drug Info
Cross-matching ID
TTD Drug ID
DMFWXPS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [2]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [3]
CIPEMASTAT DM803GL Rheumatoid arthritis FA20 Phase 3 [4]
Apratastat DM8W4N9 Rheumatoid arthritis FA20 Phase 2 [5]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [1]
BMS 275291 DMKSFPE Kaposi sarcoma 2B57 Discontinued in Phase 3 [6]
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [7]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [8]
XL784 DMICR39 Diabetic nephropathy GB61.Z Discontinued in Phase 2 [9]
SC-44463 DMBPNKT N. A. N. A. Terminated [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prinomastat DM9HOKG Lung cancer 2C25.0 Approved [2]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [11]
Marimastat DM6V34C Pancreatic cancer 2C10 Phase 3 [3]
Neovastat DMXTYWJ Non-small-cell lung cancer 2C25.Y Phase 1 [12]
Metastat DMTQ4PN Acne vulgaris ED80 Phase 1 [13]
PMID29130358-Compound-Figure18(14a) DMHIBTZ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9b) DMPAQLZ N. A. N. A. Patented [1]
PMID29130358-Compound-SB-3CT DMC64XQ N. A. N. A. Patented [1]
PMID29130358-Compound-Figure16(9a) DMKX5R8 N. A. N. A. Patented [1]
PMID29130358-Compound-Figure18(14) DM7WXJ9 N. A. N. A. Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GM6001 DM7V9CT Corneal ulcer 9A76 Discontinued in Phase 2 [7]
RS-130830 DMOTANY Hepatitis C virus infection 1E51.1 Discontinued in Phase 2 [8]
PG-530742 DMELXBQ Myocardial infarction BA41-BA43 Discontinued in Phase 2 [14]
Batimastat DM92VRP Idiopathic pulmonary fibrosis CB03.4 Preclinical [15]
SC-44463 DMBPNKT N. A. N. A. Terminated [16]
BB-1101 DM7GH5Z Multiple sclerosis 8A40 Terminated [17]
L-696418 DMV785R N. A. N. A. Terminated [18]
RO-319790 DML3NEU Rheumatoid arthritis FA20 Terminated [19]
MMI270 DM38N2K Discovery agent N.A. Investigative [13]
IK-862 DMJA4UE Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Matrix metalloproteinase-1 (MMP-1) TTMX39J MMP1_HUMAN Inhibitor [1]
Matrix metalloproteinase-2 (MMP-2) TTLM12X MMP2_HUMAN Inhibitor [1]
Matrix metalloproteinase-3 (MMP-3) TTUZ2L5 MMP3_HUMAN Inhibitor [1]

References

1 Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
2 AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45.
3 Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81.
4 Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8.
5 Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9.
6 Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8.
7 Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
8 Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
9 Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63.
10 A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25.
11 Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4.
12 Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5.
13 Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.
14 Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
15 Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
16 Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
17 Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
18 Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
19 The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
20 Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7.